...
首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials.
【24h】

Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials.

机译:在欧洲化妆品协会(COLIPA)环试验中预测人类细胞系激活测试(h-CLAT)的皮肤致敏潜力和实验室间可重复性。

获取原文
获取原文并翻译 | 示例
           

摘要

Regulatory policies in Europe prohibited the testing of cosmetic ingredients in animals for a number of toxicological endpoints. Currently no validated non-animal test methods exist for skin sensitization. Evaluation of changes in cell surface marker expression in dendritic cell (DC)-surrogate cell lines represents one non-animal approach. The human Cell Line Activation Test (h-CLAT) examines the level of CD86 and CD54 expression on the surface of THP-1 cells, a human monocytic leukemia cell line, following 24h of chemical exposure. To examine protocol transferability, between-lab reproducibility, and predictive capacity, the h-CLAT has been evaluated by five independent laboratories in several ring trials (RTs) coordinated by the European Cosmetics Association (COLIPA). The results of the first and second RTs demonstrated that the protocol was transferable and basically had good between-lab reproducibility and predictivity, but there were some false negative data. To improve performance, protocol and prediction model were modified. Using the modified prediction model in the first and second RT, accuracy was improved. However, about 15% of the outcomes were not correctly identified, which exposes some of the limitations of the assay. For the chemicals evaluated, the limitation may due to chemical being a weak allergen or having low solubility (ex. alpha-hexylcinnamaldehyde). The third RT evaluated the modified prediction model and satisfactory results were obtained. From the RT data, the feasibility of utilizing cell lines as surrogate DC in development of in vitro skin sensitization methods shows promise. The data also support initiating formal pre-validation of the h-CLAT in order to fully understand the capabilities and limitations of the assay.
机译:欧洲的监管政策禁止对动物的化妆品成分进行多种毒理学终点测试。目前,尚无针对皮肤过敏的经过验证的非动物测试方法。评估树突状细胞(DC)替代细胞系中细胞表面标志物表达的变化代表一种非动物方法。人类细胞系激活测试(h-CLAT)在化学暴露24小时后检查THP-1细胞(人类单核细胞白血病细胞系)表面CD86和CD54的表达水平。为了检查实验方案的可转移性,实验室间的可重复性和预测能力,h-CLAT已由五个独立实验室在欧洲化妆品协会(COLIPA)协调的多个环试验(RT)中进行了评估。第一次和第二次RT的结果表明,该方案是可移植的,并且基本上具有良好的实验室间再现性和可预测性,但是存在一些假阴性数据。为了提高性能,对协议和预测模型进行了修改。在第一和第二RT中使用修改后的预测模型,可以提高准确性。但是,大约15%的结果未正确识别,这暴露了该测定法的某些局限性。对于所评估的化学药品,其局限性可能是由于化学药品的过敏原弱或溶解度低(例如,α-己基肉桂醛)。第三轮RT对改进的预测模型进行了评估,并获得了满意的结果。从RT数据来看,在开发体外皮肤敏化方法中利用细胞系作为替代DC的可行性显示出希望。数据还支持对h-CLAT进行正式的预验证,以便充分了解测定的功能和局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号